Accuray Receives FDA Clearance
News Jul 02, 2016
Accuray Incorporated has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact™ Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System.
These next generation hardware and software solutions which, together, make up the new Radixact system, enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients, including those undergoing retreatment. The new Radixact system represents a major step forward in the evolution of the TomoTherapy® System in treatment speed and ease of use.
The system features a more powerful linear accelerator, MVCT imaging and helical treatment delivery, so clinicians can apply highly conformal and homogenous dose distributions to any target volume, while precisely sparing normal healthy tissue during each treatment fraction. The new Accuray Precision Treatment Planning System with smart, automated workflows and midcourse decision-making tools, enables clinicians to adapt delivery to changes in tumor size, shape and location within the patient.
“The Radixact System gives the radiation therapy team expanded capabilities across the widest range of patient cases, from the routine to the most complex, with precision, speed and efficient workflows,” said Joshua H. Levine, president and chief executive officer of Accuray. According to Jennifer Smilowitz, PhD, clinical associate professor University of Wisconsin School of Medicine and Public Health, who was involved in the development of the new radiation therapy technology, “The Radixact System builds upon the unique strengths of the TomoTherapy platform.
Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT, an extremely accurate form of radiation therapy) to an expanded range of patients. New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department.” Accuray will initiate commercial release of the Radixact System late in the first quarter of fiscal year 2017.
Susan Audino Joins CloudLIMS’ Scientific Advisory BoardNews
Dr. Susan Audino, Chair of the Cannabis Working Group at AOAC International, has joined the Scientific Advisory Board at CloudLIMS, which specialises in data management solutions for cannabis testing laboratories.READ MORE
Insulin Goes Viral: Diabetes and Cancer-causing Mechanisms ExploredNews
Every cell in your body responds to the hormone insulin, and if that process starts to fail, you get diabetes. In an unexpected finding, scientists have identified four viruses that can produce insulin-like hormones that are active on human cells. The discovery brings new possibilities for revealing biological mechanisms that may cause diabetes or cancer.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Comments | 0 ADD COMMENT
4th International Conference on Crystallography & Novel Materials
Nov 19 - Nov 20, 2018